Skip to main content
Premium Trial:

Request an Annual Quote

Xenon and Genentech Ink Rx, Companion Dx Collaboration and License Pact

NEW YORK (GenomeWeb News) – Canadian drug discovery firm Xenon said this week that it will collaborate with Genentech to discover and develop compounds and companion diagnostics for treating pain.

The pact could bring Burnaby, BC-based Xenon up to $646 million in total payments.

The agreement gives Genentech a non-exclusive license to develop and commercialize diagnostics developed under the collaboration and an exclusive license to compounds, Xenon said.

Xenon will receive an undisclosed upfront payment, research funding, and payments for research, development, and commercialization milestones, as well as royalties on sales of products resulting from the collaboration.

Xenon's discovery and development efforts focus on development of small-molecule therapies based on the genetic causes of metabolic, neurological, and cardiovascular diseases.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more